Cary Pharmaceuticals is a pharmaceutical development company. The Company is advancing the development of its three products, QuitPak®, CPI-300, and Tempol while leveraging $3.2 million in financing from its strategic development partners, Catalent Pharma Solutions and Intelgenx, and $10.8 million in NIH grants. The Company is led by an experienced management team and Board of Directors, including Douglas Cary (President), a former Abbott Laboratories executive; Carl Schwan (CFO), a former CFO for two successful initial public offerings that raised $80 million; Dr. Lester Crawford (Director), Former Commissioner of the U.S. Food and Drug Administration (FDA); and Stephen Norris (Director), Co-founder and Past President of the Carlyle Group and Chairman of SN Partners, a private equity investment firm.
